PriceTargets.com logo

NASDAQ:ARVN - Arvinas Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $105.91
  • Forecasted Upside: 35.75 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$78.02 As of 03/1/2021 03:40 PM ET
▼ -0.28 (-0.36%)
1 month | 3 months | 12 months
Get New Arvinas Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARVN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARVN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$105.91
▲ +35.75% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $105.91, with a high forecast of $129.00 and a low forecast of $45.00. The average price target represents a 35.75% upside from the last price of $78.02.
Buy
The current consensus among 9 contributing investment analysts is to buy stock in Arvinas. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/8/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/7/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/6/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/19/2021OppenheimerBoost Price Target$80.00 ➝ $100.00Low
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
1/5/2021Cantor FitzgeraldBoost Price TargetOverweight$66.00 ➝ $121.00N/A
i
Rating by A. Young at Cantor Fitzgerald
12/21/2020Piper SandlerBoost Price TargetOverweight$58.00 ➝ $97.00Low
i
12/15/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$43.00 ➝ $123.00High
i
12/15/2020Smith Barney CitigroupBoost Price Target$43.00 ➝ $123.00High
i
12/15/2020Roth CapitalBoost Price TargetBuy$65.00 ➝ $120.00High
i
12/14/2020HC WainwrightReiterated RatingBuy$60.00 ➝ $100.00High
i
12/14/2020BMO Capital MarketsBoost Price TargetOutperform$62.00 ➝ $114.00High
i
12/14/2020OppenheimerUpgradeMarket Perform ➝ OutperformHigh
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/14/2020The Goldman Sachs GroupBoost Price TargetBuy$78.00 ➝ $129.00High
i
12/14/2020WedbushBoost Price TargetOutperform$62.00 ➝ $93.00High
i
12/1/2020Cantor FitzgeraldLower Price Target$75.00 ➝ $66.00Medium
i
Rating by A. Young at Cantor Fitzgerald
10/9/2020Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by A. Young at Cantor Fitzgerald
10/8/2020OppenheimerReiterated RatingHoldHigh
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
8/4/2020OppenheimerInitiated CoverageHoldLow
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
6/1/2020CitigroupUpgradeNeutral ➝ Buy$45.00Medium
i
5/31/2020OppenheimerInitiated CoverageHoldLow
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/29/2020Cantor FitzgeraldReiterated RatingBuy$75.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
5/14/2020Cantor FitzgeraldReiterated RatingBuy$75.00Medium
i
Rating by Eliana Merle at Cantor Fitzgerald
5/11/2020OppenheimerInitiated CoverageMarket PerformMedium
i
5/4/2020Roth CapitalBoost Price TargetBuy$35.00 ➝ $65.00High
i
Rating by Z. Jallah at Roth Capital
4/29/2020HC WainwrightReiterated RatingBuy$50.00 ➝ $60.00Medium
i
Rating by A. Fein at HC Wainwright
4/14/2020Cantor FitzgeraldReiterated RatingBuy$75.00Low
i
Rating by Eliana Merle at Cantor Fitzgerald
3/16/2020Piper SandlerReiterated RatingBuy$58.00High
i
Rating by Edward Tenthoff at Piper Sandler
1/30/2020BMO Capital MarketsReiterated RatingOutperform$62.00High
i
1/24/2020WedbushBoost Price TargetOutperform$39.00 ➝ $60.00Medium
i
Rating by R. Driscoll at Wedbush
1/6/2020Piper Jaffray CompaniesBoost Price TargetOverweight$35.00 ➝ $58.00N/A
i
12/20/2019Cantor FitzgeraldBoost Price TargetOverweight$42.00 ➝ $75.00Low
i
Rating by E. Merle at Cantor Fitzgerald
12/19/2019HC WainwrightInitiated CoverageBuy$50.00High
i
Rating by A. Fein at HC Wainwright
11/25/2019GuggenheimInitiated CoverageBuy$50.00High
i
11/14/2019Roth CapitalInitiated CoverageBuy$35.00Medium
i
Rating by Z. Jallah at Roth Capital
11/13/2019Piper Jaffray CompaniesReiterated RatingBuy$32.00 ➝ $35.00High
i
10/24/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$23.00 ➝ $38.00Medium
i
9/24/2019WedbushInitiated CoverageOutperform$35.00 ➝ $38.00Low
i
Rating by R. Driscoll at Wedbush
9/12/2019BMO Capital MarketsInitiated CoverageOutperform$34.00High
i
8/5/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$42.00 ➝ $42.00Medium
i
Rating by E. Merle at Cantor Fitzgerald
6/5/2019CitigroupDowngradeBuy ➝ Neutral$21.00 ➝ $22.00High
i
5/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$23.00 ➝ $32.00High
i
4/11/2019Evercore ISIInitiated CoverageOutperformHigh
i
10/22/2018CitigroupInitiated CoverageBuy ➝ Buy$21.00Low
i
10/22/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$17.00High
i
10/22/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$23.00High
i
(Data available from 3/1/2016 forward)
Arvinas logo
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.
Read More

Today's Range

Now: $78.02
$76.66
$79.80

50 Day Range

MA: $81.07
$68.70
$91.37

52 Week Range

Now: $78.02
$19.68
$92.77

Volume

9,679 shs

Average Volume

525,147 shs

Market Capitalization

$3.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Arvinas?

The following Wall Street research analysts have issued reports on Arvinas in the last year: BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, Smith Barney Citigroup, The Goldman Sachs Group, Inc., Wedbush, and Zacks Investment Research.
View the latest analyst ratings for ARVN.

What is the current price target for Arvinas?

11 Wall Street analysts have set twelve-month price targets for Arvinas in the last year. Their average twelve-month price target is $105.91, suggesting a possible upside of 35.7%. The Goldman Sachs Group, Inc. has the highest price target set, predicting ARVN will reach $129.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $45.00 for Arvinas in the next year.
View the latest price targets for ARVN.

What is the current consensus analyst rating for Arvinas?

Arvinas currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARVN will outperform the market and that investors should add to their positions of Arvinas.
View the latest ratings for ARVN.

What other companies compete with Arvinas?

Other companies that are similar to Arvinas include BioMarin Pharmaceutical, Teva Pharmaceutical Industries, Grifols, Bausch Health Companies, BridgeBio Pharma, Mirati Therapeutics, Dr. Reddy's Laboratories, Ultragenyx Pharmaceutical, Jazz Pharmaceuticals, Zai Lab, Ascendis Pharma A/S, Arrowhead Pharmaceuticals, ACADIA Pharmaceuticals, United Therapeutics and Ionis Pharmaceuticals.

How do I contact Arvinas' investor relations team?

Arvinas' physical mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company's listed phone number is 203-535-1456 and its investor relations email address is [email protected] The official website for Arvinas is www.arvinas.com.